These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 30849373)

  • 1. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.
    Marcandalli J; Fiala B; Ols S; Perotti M; de van der Schueren W; Snijder J; Hodge E; Benhaim M; Ravichandran R; Carter L; Sheffler W; Brunner L; Lawrenz M; Dubois P; Lanzavecchia A; Sallusto F; Lee KK; Veesler D; Correnti CE; Stewart LJ; Baker D; Loré K; Perez L; King NP
    Cell; 2019 Mar; 176(6):1420-1431.e17. PubMed ID: 30849373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.
    Boyington JC; Joyce MG; Sastry M; Stewart-Jones GB; Chen M; Kong WP; Ngwuta JO; Thomas PV; Tsybovsky Y; Yang Y; Zhang B; Chen L; Druz A; Georgiev IS; Ko K; Zhou T; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2016; 11(7):e0159709. PubMed ID: 27463224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
    Mukhamedova M; Wrapp D; Shen CH; Gilman MSA; Ruckwardt TJ; Schramm CA; Ault L; Chang L; Derrien-Colemyn A; Lucas SAM; Ransier A; Darko S; Phung E; Wang L; Zhang Y; Rush SA; Madan B; Stewart-Jones GBE; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Doria-Rose NA; Morabito KM; DeKosky BJ; Gaudinski MR; Chen GL; Crank MC; Misasi J; Sullivan NJ; Douek DC; Kwong PD; Graham BS; McLellan JS; Mascola JR
    Immunity; 2021 Apr; 54(4):769-780.e6. PubMed ID: 33823129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.
    Sastry M; Zhang B; Chen M; Joyce MG; Kong WP; Chuang GY; Ko K; Kumar A; Silacci C; Thom M; Salazar AM; Corti D; Lanzavecchia A; Taylor G; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2017; 12(10):e0186854. PubMed ID: 29073183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.
    Stewart-Jones GB; Thomas PV; Chen M; Druz A; Joyce MG; Kong WP; Sastry M; Soto C; Yang Y; Zhang B; Chen L; Chuang GY; Georgiev IS; McLellan JS; Srivatsan S; Zhou T; Baxa U; Mascola JR; Graham BS; Kwong PD
    PLoS One; 2015; 10(6):e0128779. PubMed ID: 26098893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain.
    Swanson KA; Rainho-Tomko JN; Williams ZP; Lanza L; Peredelchuk M; Kishko M; Pavot V; Alamares-Sapuay J; Adhikarla H; Gupta S; Chivukula S; Gallichan S; Zhang L; Jackson N; Yoon H; Edwards D; Wei CJ; Nabel GJ
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32358170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    Stephens LM; Ross KA; McLellan JS; Narasimhan B; Varga SM
    J Virol; 2022 Nov; 96(22):e0150222. PubMed ID: 36314826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
    McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
    J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.